APO Research
Talk to an analyst

APO RESEARCH · REPORT

VHH Antibody Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global VHH Antibody Drugs Market Outlook and Growth Opportunities 2026

29 December 2025193 pages

Choose your research edition.

Industry ResearchVHH Antibody Drugs Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal VHH Antibody Drugs Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal VHH Antibody Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal VHH Antibody Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal VHH Antibody Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global VHH Antibody Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for VHH Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for VHH Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for VHH Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the VHH Antibody Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the VHH Antibody Drugs market include Janssen Pharmaceuticals, Sanofi Company(Ablynx), Alphamab Oncology and Legend Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global VHH Antibody Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of VHH Antibody Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents VHH Antibody Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the VHH Antibody Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

VHH Antibody Drugs Segment by Company

Janssen Pharmaceuticals

Sanofi Company(Ablynx)

Alphamab Oncology

Legend Biotech

VHH Antibody Drugs Segment by Type

Monovalent Nanobody

Bivalent Nanobody

Bispecific Nanobody

Others

VHH Antibody Drugs Segment by Application

Hospital

Clinic

Other

VHH Antibody Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global VHH Antibody Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions VHH Antibody Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify VHH Antibody Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze VHH Antibody Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global VHH Antibody Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of VHH Antibody Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of VHH Antibody Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the VHH Antibody Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global VHH Antibody Drugs industry.

Chapter 3: Detailed analysis of VHH Antibody Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of VHH Antibody Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of VHH Antibody Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. VHH Antibody Drugs Industry Trends Table 2. VHH Antibody Drugs Industry Drivers Table 3. VHH Antibody Drugs Industry Opportunities and Challenges Table 4. VHH Antibody Drugs Industry Restraints Table 5. Global VHH Antibody Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global VHH Antibody Drugs Revenue Share by Company (2021-2026) Table 7. Global VHH Antibody Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global VHH Antibody Drugs Sales Volume Share by Company (2021-2026) Table 9. Global VHH Antibody Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global VHH Antibody Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global VHH Antibody Drugs Key Company Manufacturing Base & Headquarters Table 12. Global VHH Antibody Drugs Company, Product Type & Application Table 13. Global VHH Antibody Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global VHH Antibody Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Monovalent Nanobody Table 18. Significant Companies of Bivalent Nanobody Table 19. Significant Companies of Bispecific Nanobody Table 20. Significant Companies of Others Table 21. Global VHH Antibody Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global VHH Antibody Drugs Sales Volume by Type (2021-2026) & (K Units) Table 23. Global VHH Antibody Drugs Sales Volume by Type (2027-2032) & (K Units) Table 24. Global VHH Antibody Drugs Sales Volume Share by Type (2021-2026) Table 25. Global VHH Antibody Drugs Sales Volume Share by Type (2027-2032) Table 26. Global VHH Antibody Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global VHH Antibody Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global VHH Antibody Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global VHH Antibody Drugs Sales Value Share by Type (2021-2026) Table 30. Global VHH Antibody Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Other Table 34. Global VHH Antibody Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global VHH Antibody Drugs Sales Volume by Application (2021-2026) & (K Units) Table 36. Global VHH Antibody Drugs Sales Volume by Application (2027-2032) & (K Units) Table 37. Global VHH Antibody Drugs Sales Volume Share by Application (2021-2026) Table 38. Global VHH Antibody Drugs Sales Volume Share by Application (2027-2032) Table 39. Global VHH Antibody Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global VHH Antibody Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global VHH Antibody Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global VHH Antibody Drugs Sales Value Share by Application (2021-2026) Table 43. Global VHH Antibody Drugs Sales Value Share by Application (2027-2032) Table 44. Global VHH Antibody Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global VHH Antibody Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global VHH Antibody Drugs Sales Market Share by Region (2021-2026) Table 47. Global VHH Antibody Drugs Sales by Region (2027-2032) & (K Units) Table 48. Global VHH Antibody Drugs Sales Market Share by Region (2027-2032) Table 49. Global VHH Antibody Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global VHH Antibody Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global VHH Antibody Drugs Sales Value Share by Region (2021-2026) Table 52. Global VHH Antibody Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global VHH Antibody Drugs Sales Value Share by Region (2027-2032) Table 54. Global VHH Antibody Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global VHH Antibody Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global VHH Antibody Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global VHH Antibody Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global VHH Antibody Drugs Sales by Country (2021-2026) & (K Units) Table 59. Global VHH Antibody Drugs Sales Market Share by Country (2021-2026) Table 60. Global VHH Antibody Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global VHH Antibody Drugs Sales Market Share by Country (2027-2032) Table 62. Global VHH Antibody Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global VHH Antibody Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global VHH Antibody Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global VHH Antibody Drugs Sales Value Market Share by Country (2027-2032) Table 66. Janssen Pharmaceuticals Company Information Table 67. Janssen Pharmaceuticals Business Overview Table 68. Janssen Pharmaceuticals VHH Antibody Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Janssen Pharmaceuticals VHH Antibody Drugs Product Portfolio Table 70. Janssen Pharmaceuticals Recent Development Table 71. Sanofi Company(Ablynx) Company Information Table 72. Sanofi Company(Ablynx) Business Overview Table 73. Sanofi Company(Ablynx) VHH Antibody Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Sanofi Company(Ablynx) VHH Antibody Drugs Product Portfolio Table 75. Sanofi Company(Ablynx) Recent Development Table 76. Alphamab Oncology Company Information Table 77. Alphamab Oncology Business Overview Table 78. Alphamab Oncology VHH Antibody Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Alphamab Oncology VHH Antibody Drugs Product Portfolio Table 80. Alphamab Oncology Recent Development Table 81. Legend Biotech Company Information Table 82. Legend Biotech Business Overview Table 83. Legend Biotech VHH Antibody Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Legend Biotech VHH Antibody Drugs Product Portfolio Table 85. Legend Biotech Recent Development Table 86. Key Raw Materials Table 87. Raw Materials Key Suppliers Table 88. VHH Antibody Drugs Distributors List Table 89. VHH Antibody Drugs Customers List Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. VHH Antibody Drugs Product Image Figure 2. Global VHH Antibody Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global VHH Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global VHH Antibody Drugs Sales (2021-2032) & (K Units) Figure 5. Global VHH Antibody Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global VHH Antibody Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Monovalent Nanobody Image Figure 10. Bivalent Nanobody Image Figure 11. Bispecific Nanobody Image Figure 12. Others Image Figure 13. Global VHH Antibody Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global VHH Antibody Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global VHH Antibody Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global VHH Antibody Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global VHH Antibody Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global VHH Antibody Drugs Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Other Image Figure 22. Global VHH Antibody Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global VHH Antibody Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global VHH Antibody Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global VHH Antibody Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global VHH Antibody Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global VHH Antibody Drugs Sales Value Share by Application (2021-2032) Figure 28. Global VHH Antibody Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global VHH Antibody Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global VHH Antibody Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global VHH Antibody Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America VHH Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America VHH Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe VHH Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe VHH Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific VHH Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific VHH Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America VHH Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America VHH Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa VHH Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa VHH Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt VHH Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. VHH Antibody Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. VHH Antibody Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Monovalent Nanobody
  • Bivalent Nanobody
  • Bispecific Nanobody
  • Others
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Janssen Pharmaceuticals
  • Sanofi Company(Ablynx)
  • Alphamab Oncology
  • Legend Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global VHH Antibody Drugs Sales Value (2021-2032)
  4. 1.2.2 Global VHH Antibody Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global VHH Antibody Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 VHH Antibody Drugs Market Dynamics
  1. 2.1 VHH Antibody Drugs Industry Trends
  2. 2.2 VHH Antibody Drugs Industry Drivers
  3. 2.3 VHH Antibody Drugs Industry Opportunities and Challenges
  4. 2.4 VHH Antibody Drugs Industry Restraints
3 VHH Antibody Drugs Market by Company
  1. 3.1 Global VHH Antibody Drugs Company Revenue Ranking in 2025
  2. 3.2 Global VHH Antibody Drugs Revenue by Company (2021-2026)
  3. 3.3 Global VHH Antibody Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global VHH Antibody Drugs Average Price by Company (2021-2026)
  5. 3.5 Global VHH Antibody Drugs Company Ranking (2024-2026)
  6. 3.6 Global VHH Antibody Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global VHH Antibody Drugs Company Product Type and Application
  8. 3.8 Global VHH Antibody Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global VHH Antibody Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 VHH Antibody Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 VHH Antibody Drugs Market by Type
  1. 4.1 VHH Antibody Drugs Type Introduction
  2. 4.1.1 Monovalent Nanobody
  3. 4.1.2 Bivalent Nanobody
  4. 4.1.3 Bispecific Nanobody
  5. 4.1.4 Others
  6. 4.2 Global VHH Antibody Drugs Sales Volume by Type
  7. 4.2.1 Global VHH Antibody Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global VHH Antibody Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global VHH Antibody Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global VHH Antibody Drugs Sales Value by Type
  11. 4.3.1 Global VHH Antibody Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global VHH Antibody Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global VHH Antibody Drugs Sales Value Share by Type (2021-2032)
5 VHH Antibody Drugs Market by Application
  1. 5.1 VHH Antibody Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global VHH Antibody Drugs Sales Volume by Application
  6. 5.2.1 Global VHH Antibody Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global VHH Antibody Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global VHH Antibody Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global VHH Antibody Drugs Sales Value by Application
  10. 5.3.1 Global VHH Antibody Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global VHH Antibody Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global VHH Antibody Drugs Sales Value Share by Application (2021-2032)
6 VHH Antibody Drugs Regional Sales and Value Analysis
  1. 6.1 Global VHH Antibody Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global VHH Antibody Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global VHH Antibody Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global VHH Antibody Drugs Sales by Region (2027-2032)
  5. 6.3 Global VHH Antibody Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global VHH Antibody Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global VHH Antibody Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global VHH Antibody Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global VHH Antibody Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America VHH Antibody Drugs Sales Value (2021-2032)
  12. 6.6.2 North America VHH Antibody Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe VHH Antibody Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe VHH Antibody Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific VHH Antibody Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific VHH Antibody Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America VHH Antibody Drugs Sales Value (2021-2032)
  21. 6.9.2 South America VHH Antibody Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa VHH Antibody Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa VHH Antibody Drugs Sales Value Share by Country, 2025 VS 2032
7 VHH Antibody Drugs Country-level Sales and Value Analysis
  1. 7.1 Global VHH Antibody Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global VHH Antibody Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global VHH Antibody Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global VHH Antibody Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global VHH Antibody Drugs Sales by Country (2027-2032)
  6. 7.4 Global VHH Antibody Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global VHH Antibody Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global VHH Antibody Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt VHH Antibody Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt VHH Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt VHH Antibody Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Janssen Pharmaceuticals
  2. 8.1.1 Janssen Pharmaceuticals Company Information
  3. 8.1.2 Janssen Pharmaceuticals Business Overview
  4. 8.1.3 Janssen Pharmaceuticals VHH Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Janssen Pharmaceuticals VHH Antibody Drugs Product Portfolio
  6. 8.1.5 Janssen Pharmaceuticals Recent Developments
  7. 8.2 Sanofi Company(Ablynx)
  8. 8.2.1 Sanofi Company(Ablynx) Company Information
  9. 8.2.2 Sanofi Company(Ablynx) Business Overview
  10. 8.2.3 Sanofi Company(Ablynx) VHH Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Company(Ablynx) VHH Antibody Drugs Product Portfolio
  12. 8.2.5 Sanofi Company(Ablynx) Recent Developments
  13. 8.3 Alphamab Oncology
  14. 8.3.1 Alphamab Oncology Company Information
  15. 8.3.2 Alphamab Oncology Business Overview
  16. 8.3.3 Alphamab Oncology VHH Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Alphamab Oncology VHH Antibody Drugs Product Portfolio
  18. 8.3.5 Alphamab Oncology Recent Developments
  19. 8.4 Legend Biotech
  20. 8.4.1 Legend Biotech Company Information
  21. 8.4.2 Legend Biotech Business Overview
  22. 8.4.3 Legend Biotech VHH Antibody Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Legend Biotech VHH Antibody Drugs Product Portfolio
  24. 8.4.5 Legend Biotech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 VHH Antibody Drugs Value Chain Analysis
  2. 9.1.1 VHH Antibody Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 VHH Antibody Drugs Sales Mode & Process
  6. 9.2 VHH Antibody Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 VHH Antibody Drugs Distributors
  9. 9.2.3 VHH Antibody Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst